poisar

Stocks · News reference

Japan Patent Office Grants Patent for XORTX Therapeutics' XRx-101 Program

Fiscal.ai

The Japan Patent Office has issued a decision to grant a patent for XORTX Therapeutics' XRx-101 program, covering compositions and formulations for treating acute kidney injury associated with respiratory viral infections.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    XORTX Patent Allowed for XRx-101 Program by Japan Patent Office

    XORTX Therapeutics announced that the Japan Patent Office has issued a Decision to Grant a patent for its xanthine oxidase inhibitor compositions (XRx-101) for treating acute kidney injury and other health consequences of viral infections. The patent, expected to remain in force until March 2041, marks the company's first patent protection in Japan and strengthens its intellectual property position in one of the world's largest pharmaceutical markets.